Initiation of Tocilizumab or Baricitinib Were Associated With Comparable Clinical Outcomes Among Patients Hospitalized With COVID-19 and Treated With Dexamethasone
Objectives: This retrospective cohort study aims to explore head-to-head clinical outcomes and complications associated with tocilizumab or baricitinib initiation among hospitalized COVID-19 patients receiving dexamethasone.Methods: Among 10,445 COVID-19 patients hospitalized between January 21st 20...
Main Authors: | Carlos K. H. Wong, Kristy T. K. Lau, Ivan C. H. Au, Xi Xiong, Matthew S. H. Chung, Belle Y. C. Leung, Eric H. Y. Lau, Benjamin J. Cowling |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2022-05-01
|
Series: | Frontiers in Pharmacology |
Subjects: | |
Online Access: | https://www.frontiersin.org/articles/10.3389/fphar.2022.866441/full |
Similar Items
-
Comparative Efficacy of Tocilizumab and Baricitinib Administration in COVID-19 Treatment: A Retrospective Cohort Study
by: Yuichi Kojima, et al.
Published: (2022-04-01) -
Baricitinib plus dexamethasone compared to dexamethasone for the treatment of severe COVID-19 pneumonia: A retrospective analysis
by: Eduardo Pérez-Alba, et al.
Published: (2021-10-01) -
Is Tocilizumab Plus Dexamethasone Associated with Superinfection in Critically Ill COVID-19 Patients?
by: Fabrice Camou, et al.
Published: (2022-09-01) -
The effects of combination-therapy of tocilizumab and baricitinib on the management of severe COVID-19 cases: a randomized open-label clinical trial
by: Farzaneh Dastan, et al.
Published: (2023-10-01) -
Efficacy and safety of tocilizumab and baricitinib among patients hospitalized for COVID-19: a systematic review and meta-analysis
by: Jin Zhang, et al.
Published: (2023-11-01)